Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
3.020
-0.030 (-0.98%)
At close: Aug 14, 2026, 4:00 PM EDT
3.040
+0.020 (0.66%)
After-hours: Aug 14, 2026, 7:42 PM EDT

Niagen Bioscience Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Niagen Bioscience stock has a consensus rating of "Strong Buy" and an average price target of $12.08. The average 1-year stock price forecast is 300.00% higher than the current stock price, while the lowest is $8.50 (+181.46%) and the highest is $22 (+628.48%).

Price Target: $12.08 (+300.00%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$8.50$12.08$10.5$22
Change+181.46%+300.00%+247.68%+628.48%

Analyst Ratings

The average analyst rating for Niagen Bioscience stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingDec '25Feb '26Mar '26Apr '26May '26Jul '26
Strong Buy555556
Buy000000
Hold000000
Sell000000
Strong Sell000000
Total555556

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Canaccord Genuity
Canaccord Genuity
Buy
Reiterates
$10
BuyReiterates$10+231.13%Aug 12, 2026
Roth MKM
Roth MKM
Buy
Maintains
$12$10
BuyMaintains$12$10+231.13%Aug 5, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$11
BuyReiterates$11+264.24%Aug 5, 2026
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
Buy
Maintains
$12$11
BuyMaintains$12$11+264.24%Jul 21, 2026
Freedom Capital Markets
Freedom Capital Markets
Buy
Initiates
$9
BuyInitiates$9+198.01%Jul 6, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
133.11M
from 129.42M
Increased by 2.85%
Revenue Next Year
155.31M
from 133.11M
Increased by 16.67%
EPS This Year
0.09
from 0.17
Decreased by -46.24%
EPS Next Year
0.10
from 0.09
Increased by 11.11%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
67.45M72.05M83.57M99.60M129.42M133.11M
Revenue Growth
13.83%6.82%15.99%19.18%29.95%2.85%
Gross Profit
41.49M42.80M50.78M61.59M83.19M85.28M
Gross Margin
61.51%59.40%60.76%61.84%64.28%64.07%
Operating Income
-27.07M-18.63M-5.60M7.73M14.30M5.19M
Net Income
-27.13M-16.54M-4.94M8.55M17.38M10.88M
EPS
----0.170.09
EPS Growth
----238.18%-46.24%
Forward PE
160.00160.00160.0050.2827.8133.56
Free Cash Flow
-13.50M-9.64M9.47M9.61M5.55M17.40M
No. Analysts
-----5
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High134.9M
Avg133.1M
Low130.3M

Revenue Growth

Revenue Growth202620272028
High
4.2%
Avg
2.9%
Low
0.6%

EPS Forecast

EPS202620272028
High0.09
Avg0.09
Low0.09

EPS Growth

EPS Growth202620272028
High
-46.2%
Avg
-46.2%
Low
-46.2%